Back to results
US 12,601,743 B2Granted
Methods for treating drug resistant cancers
AssigneeThe Regents of the University of California
InventorsDavid Cheresh, Sara Weis, Erika Cosset
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeThe Regents of the University of California
InventorsDavid Cheresh, Sara Weis, Erika Cosset
Estimating the term…
Provided are methods for determining whether a glioblastoma (GBM) tumor or GBM cancer cell will be sensitive to a treatment targeting the integrin avb3 (αvβ3) pathway, comprising determining whether the GBM tumor or the GBM cancer cell expresses both avb3+ and Glut3+ along with a specific genetic signature associated with Glut3 addiction, where in alternative embodiments a cell is Glut3 addiction if the GBM tumor or the GBM cancer cell has markers consistent with the Classical or the Proneural molecular subtypes of GBM, or, expresses markers consistent with a Glut3-addicted molecular signature, e.g., as listed in FIG. 11 or FIG. 23. Also provided herein are methods of treating glioblastoma (GBM) tumors found to be sensitive to agents targeting or inhibiting the integrin avb3 (αvβ3) pathway, wherein the sensitivity is determined by methods as provided herein.
A method for treating or ameliorating, or killing, or inducing into senescence, a tumor or a cancer cell in an individual in need thereof, the method comprising:
A method for treating or ameliorating, or killing, or inducing into senescence, a melanoma or a primitive neuroectodermal tumor (PNET) in an individual in need thereof, the method comprising:
Dependencies are inferred from the claim text.